Destiny Pharma has announed that Sir Nigel Rudd is stepping down as chairman and a member of the Board after serving eight years and having made his first investment in the Company in 2003.

Nick Rodgers, non-executive director of Destiny, will become chairman following Sir Nigel’s departure on 31 December 2018. Nick has considerable Board experience in both public and private growth companies, particularly those in the life science sector, as well as a background as a successful corporate financier and investment banker. Nick is currently chairman of SEHTA, one of the largest health technology networking organisations in the UK. Prior to this, he was non-executive director and then chairman of Oxford Biomedica, a leading gene-based biopharmaceutical company.